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Introduction
Rheumatoid arthritis (RA) is a complex inflammatory disease, 
characterized by an abundant cellular infiltration consisting of 
neutrophils, macrophages, and lymphocytes, leading to the release of 
multiple inflammatory cytokines and matrix-degrading enzymes that 
contribute to the progressive joint destruction [1]. These inflammatory 
cytokines, including TNF-α and IL-1β, have been reported to induce an 
endoplasmic reticulum (ER) stress response, leading to the accumulation 
of unfolded/misfolded, polyubiquitinated protein aggregates that can 
initiate and perpetuate inflammation [2,3]. Effective removal of these 
toxic factors can help relieve cell stress, reinstate ER homeostasis, and 
curtail the inflammation. Autophagy (also known as macroautophagy) 
is involved in a number of cellular homeostatic processes and plays a 
central role in the innate and adaptive immune response by recycling 
and removing harmful protein aggregates and damaged cell organelles 
[4,5]. The dysregulation of autophagic pathways has also been implicated 
in the pathogenesis of various disease processes, such as tumorigenesis 
and inflammation [6,7]. Autophagy has been implicated in RA; however, 
its exact contribution to disease manifestation is unclear. Metformin, a 
biguanide, is the first-line oral therapy for type 2 diabetes and the most 
widely used antidiabetic drug, alone or in combination with other 
antihyperglycemic agents [8]. Metformin acutely decreases hepatic 
glucose production through direct inhibition of the mitochondrial 
respiratory chain complex I [9]. More recently, much attention has been 
given to the effects of metformin in reducing cancer risk in patients with 
type 2 diabetes [10]. It has been proposed that metformin derived anti-
cancer effects through the activation of AMP-activated protein kinase 
(AMPK) and negative regulation of mammalian target of rapamycin 
(mTOR) [11], both of which are implicated in the autophagy signaling 
network [12]. Since autophagy recently emerged as a central regulator 
in the induction and maintenance of inflammation [6], we sought to 
determine whether modulation of autophagy, through metformin-
mediated AMPK activation, would mitigate the inflammation in 
experimental arthritis. We found that autophagy was indeed initiated 
in experimental arthritis; however, autophagic flux was severely 
impaired. Metformin-mediated inhibition of mTOR activity induced 
the progression of autophagic flux, which resulted in the suppression of 
NF-κB signaling and inflammatory cytokine production. These findings 
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suggest a central role for autophagy in inflammatory arthritis and argue 
that autophagy modulators such as metformin may represent potential 
therapeutic agents for the treatment of RA.
Results
Metformin suppresses experimental arthritis
Experimental arthritis was induced with the passive transfer of 
serum from the KRN/I-Ag7 (K/BxN) mice [13]. The disease caused 
by arthrogenic autoantibodies in KRN serum shares many features 
with human RA [14]. WT C57BL/6 mice were injected i.p. with 175µl 
of KRN serum on day 0. Clinical arthritis was evident after 24 h and 
maximal disease developed around day 6-7. Metformin [150mg/
kg] was injected i.p. every day, starting on day -1 and continued for 
the duration of the experiment. Metformin treatment significantly 
suppressed clinical disease compared with saline control (Figure 1A). 
In parallel with improved clinical scores, we observed on histological 
analysis a marked decrease in inflammatory cell influx, bone erosions, 
and cartilage degradation (Figure 1B,1C). Moreover, joint-associated 
inflammatory cytokines (TNF-α, IL-1β, IL-6, MCP-1) levels on day 9 
were all significantly suppressed in the metformin treatment group 
(Figure 1D). Even when metformin treatment was delayed until day 
2 post-KRN serum administration, when arthritis is established, 
we still observed significant suppression of disease activity (Figure 
1E). Taken together these results suggest that metformin is effective 
at suppressing arthritis especially when started early or during the 
preclinical phase of the disease when there are elevations of disease-
related biomarkers (i.e. anti-citrullinated peptide antibodies and/or 
rheumatoid factor) but no overt joint symptoms [15,16].
Metformin directly suppresses macrophage inflammatory 
activity in vitro
Previous studies suggest that metformin suppressed anti-collagen 
antibody-induced arthritis through down regulation of Th17 cell 
differentiation [17,18]. However, it has been shown that in the 
standard KRN serum transfer arthritis model, the downstream effector 
mechanisms involved in disease manifestation induced by arthrogenic 
autoantibodies do not require T or B lymphocytes nor are they 
dependent on IL-17 [19,20]. We thus reasoned that metformin might 
have a more direct effect on the innate immune response that initiated 
the inflammatory cascade in KRN serum transfer arthritis. A key study 
by Zhou et al. [21] suggests that metformin activates AMP-activated 
protein kinase (AMPK) [21], a major intracellular energy sensor and 
regulator of energy homeostasis [22]. AMPK has more recently been 
linked to the regulation of inflammatory signaling, especially macrophage 
inflammatory response [23,24]. Thus, we next evaluated the cytokine 
profile of inflammatory peritoneal macrophages ex vivo in response 
to metformin. Indeed, metformin dose-dependently suppressed the 
release of TNF-α, IL-6, and MCP-1 by macrophages while enhancing 
the release of IL-10 (Figure 2A). In parallel with the anti-inflammatory 
cytokine profile, we also observed a dose-dependent increase in the 
phosphorylation of AMPK (Figure 2B).
Metformin suppresses inflammatory macrophage 
phenotype in KRN arthritis
Macrophages are central to the pathogenesis of RA. Activated 
macrophages in RA synovium produce inflammatory cytokines 
         
 
Figure 1: Metformin suppresses KRN arthritis. 
(A) Cohorts of mice were injected i.p daily with saline or metformin (150 mg/kg of body weight) starting one day prior (day -1) to KRN serum transfer and 
continued daily for the duration of the experiment. On day 0, they were injected i.p. with 175µl of KRN serum. Changes in arthritis score and ankle thickness were 
assessed daily. (B) Representative micrographs of day 9 joint sections stained with H&E and toluidine blue. Scale bars=200µm (H&E), 50 µm (toluidine blue) (C) 
Graphical representations of inflammatory cellular infiltrates, bone erosions and cartilage degradation. (D) Day 9 paws were homogenized and cleared lysates 
were assayed for inflammatory cytokines. Levels are expressed as picograms (pg) per mg of total protein extracts. (E) Arthritis was induced with KRN serum 
transfer on day 0 and metformin started on day 0 or day 2 after disease is established. Values are presented as mean ± SEM, n=15 mice in the saline group and 
5 mice for each metformin treatment group. *P<0.05, **P<0.01, ***P<0.001.
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Figure 2: Metformin directly suppresses macrophage inflammatory activity in vitro. 
(A) Day 5 thioglycollate-elicited peritoneal macrophages were cultured with the indicated metformin concentrations. At 48 h, supernatants were collected 
and assayed for cytokines by cytometric bead arrays. Values represent mean ± SEM of triplicate samples derived from 3 independent experiments. *P<0.05, 
**P<0.01, ***P<0.001 (B) Cultured macrophages were lysed, cleared, fractionated by SDS-PAGE, and probed for phospho-AMPK. Actin served as control for 
protein loading.
         
 
Figure 3: Metformin suppresses inflammatory macrophage phenotype in KRN arthritis.
Day 9 paws were stained for (A) macrophages (Mac-3, green) and TNF-α (red) and (B) Mac-3 (green) and phospho-STAT1 (red). In saline control animals there 
was significant colocalization (yellow) of TNF-α and phospho-STAT1 with Mac-3+ cells (arrowheads) while metformin treatment suppressed both TNF-α and 
STAT1 activation in macrophages (arrows). DAPI (blue) stained nuclei. Scale bar=25µm
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including TNF-α, IL-1β, IL-6 [1], suggesting they are skewed toward 
the classically activated M1 phenotype via STAT1 activation [25]. 
Although alternatively activated [M2] macrophages are also found 
in RA synovium [26], the success of biologics such as anti-TNF 
agents suggests that the balance between pro- and anti-inflammatory 
cytokines is tipped toward M1 macrophages. Consistent with these 
findings we previously observed a predominance of CD206+ (mannose 
receptor, an M2 marker) macrophages in KRN arthritic paws [27]. 
Treatment with metformin, however, led to the suppression of TNF-α 
expression and STAT1 activation at the cellular level (Figure 3AB), 
suggesting that metformin exerts a counter-inflammatory effect on 
macrophage functional phenotype in vivo, thus corroborating the in 
vitro findings (Figure 2).
Metformin activates AMPK and suppresses mTOR activity 
in KRN arthritis
To determine whether metformin also modulates AMPK activity 
in vivo, paw lysates from treated animals were examined for AMPK 
phosphorylation by Western blot analysis. We observed increased 
AMPK phosphorylation in total paw lysates from metformin-
treated animals that peaked on day 7 post KRN serum transfer 
(Figure 4A). The equivalent level of phospho-AMPK in total paw 
lysates on day 9 by Western blot analysis likely reflects the reduced 
number of inflammatory cells following metformin treatment 
(Figure 1C). Indeed, we confirmed that AMPK phosphorylation 
was still significantly enhanced on day 9 in synovial macrophages 
of metformin-treated compared with saline-treated animals (Figure 
4B). AMPK is known to inhibit the activity of mTOR, a pathway 
that negatively regulates autophagy [12]. We observed a decrease 
in mTOR complex 1 (mTORC1) signaling, evidenced by decreased 
phosphorylation of mTOR and its downstream effector, ribosomal 
protein S6, in metformin-treated animals (Figure 4C,4D).
Metformin enhances autophagic flux
We next considered whether metformin-induced AMPK 
activation and mTOR inhibition enhanced autophagic activity. 
Although autophagy is implicated in RA [28,29], its specific 
contribution to disease manifestation is still unclear. We previously 
showed that autophagy was activated in KRN arthritis [27], as 
evidenced by upregulation of microtubule-associated light chain 3 
[LC3] expression, conversion of LC3-I to LC3-II by lipidation (Figure 
5A), and formation of autophagosomes, seen as punctate LC3+ 
immunofluorescent dots [30] and (Figure 5B). Although these findings 
indicate that autophagy was initiated during KRN arthritis, efficient 
progression of autophagy (autophagic flux) appeared to be impaired, 
evidenced by the accumulation of LC3-II and p62 (Figure 5A). p62, 
also known as SQSTM1/sequestome1, is an adaptor protein that 
participates in the delivery of ubiquinated proteins to autophagosomes. 
LC3-II and p62 are incorporated into autophagosomes and degraded 
during autophagic progression [30,31]. Thus, LC3-II and p62 levels 
inversely correlate with autophagic activity/flux. One explanation 
for the impaired autophagic flux in KRN arthritis could be the 
         
 
Figure 4: Metformin activates AMPK and suppresses mTORC1 activity in KRN arthritis.
(A) Protein lysates from day 5, 7, or 9 paws obtained from KRN arthritic mice were probed for p-AMPK and total AMPK. Actin served as control for protein loading. 
(B) Day 9 paws were stained for Mac-3 (arrows, green) and p-AMPK (red). Colocalization (arrowheads) appeared orange/yellow. (C) Day 9 paws were stained for 
phospho (p)-mTOR and p-S6 (red). DAPI (blue) stained nuclei. Scale bar=25µm (D) Intracellular level of p-mTOR and p-S6 was analyzed using ImageJ program 
as detailed in the Materials and Methods section and presented as integrated optical density (IntDen). Values represent mean ± SEM, n = 4-5 mice per treatment 
group. *P<0.05 compared with saline.
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blockade of fusion between autophagosomes and lysosomes to 
form autolysosomes [32]. Indeed we found minimal co-localization 
between punctate LC3+ cells and LAMP-1 (a marker of lysosomes) 
(Figure 5B) in KRN arthritis. Metformin treatment, on the other 
hand, induced the formation of autolysosomes, as evidenced by 
colocalization of LC3 and LAMP-1 (Figure 5B), and the progression 
of autophagic flux, which was reflected in decreased LC3-II and p62 
levels (Figure 5C). Initiation of the autophagic cascade also requires 
the mammalian unc-51-like kinase 1 (ULK1) complex [33]. AMPK 
(and mTORC1) are known to phosphorylate ULK1 at various sites 
but the effects of AMPK on ULK1 in the control of autophagy are 
still not well-established [33]. We found significantly lower level of 
phospho-ULK1Ser555 in day 9 metformin-treated paws, suggesting 
that dephosphorylation of ULK1 may represent an important event 
in the regulation of autophagic activity (Figure 5D).
Metformin promotes degradation of NF-κB protein Iκ 
kinase (IKK) through autophagy
There is considerable new evidence pointing to a role of 
autophagy in the clearance of cytotoxic protein aggregates that 
accumulate in disease states and alterations in autophagy-dependent 
events result in the excessive production of inflammatory cytokines 
[6]. We reasoned that metformin-induced AMPK activation 
enhanced autophagic progression and the increased flux mediated 
protein degradation through the (auto) lysosomal pathway, thus 
suppressing the inflammatory responses. NF-κB plays a central role 
in the pathogenesis of RA [34]. The NF-κB family comprises five 
members: p105 (constitutively processed to p50), p100 (processed 
to p52 under regulated conditions), p65 (also known as RelA), 
RelB, and c-Rel [35]. These members form homo- and heterodimers 
that, in the resting cell, are normally held inactive in the cytoplasm 
by the association with inhibitors, the IκB proteins. Upstream 
signaling and activation of the NF-κB pathway converge on the IκB 
kinase (IKK) complex that phosphorylates IκB proteins and targets 
them for degradation, releasing the NF-κB Rel subunits for nuclear 
translocation and transactivation of a multitude of responsive genes, 
including several inflammatory cytokines. Recent studies suggest a 
tight regulation between NF-κB pathway and autophagy [36,37]. 
Indeed Qing et al. [38] have shown that IKK proteins are substrates 
for the autophagy pathway [38]. Thus, autophagic degradation of 
IKK would potentially limit the role of NF-κB in inflammation. We 
examined various NF-κB proteins in day 9 paw lysates and observed 
specific decrease in IKK(α) level with relative preservation of IκB and 
p65 protein expression (Figure 6A) in metformin-treated animals. 
IKK(α) degradation suppressed NF-κB signaling, as evidenced by 
depressed p65 phosphorylation/activation following metformin 
treatment (Figure 6A). We further investigated how metformin 
induced IKK degradation. During the cellular stress that accompanies 
inflammatory arthritis, large quantities of newly synthesized proteins 
are polyubiquinated [39] and recognized by p62/ SQSTM1 (Figure 
6B). In fact, p62-polyubiquinated protein aggregates have recently 
been described in RA synovial cells [29]. We found that IKKα was 
indeed ubiquinated (Figure 6C) and, following metformin treatment, 
co-localized to the LAMP- 1+ compartment (Figure 6D), suggesting 
         
 
Figure 5: Metformin enhances autophagic flux.
 (A) Paw lysates from normal and day 9 KRN serum-induced arthritic mice were probed for LC3-I, the lipidated form LC3-II, and p62. Actin served as control 
for protein loading. (B) Paw sections from untreated arthritic mice or arthritic mice treated with saline or metformin were stained for LC3 (green) and the 
lysosomal marker LAMP-1 (red). Note the punctate LC3 staining in untreated or saline control arthritic paws. Colocalization of LC3 and LAMP-1 (arrow) indicates 
autolysosome. Scale bar=10µm (C) Treatment with metformin led to degradation of the lipidated LC3-II form and p62, indicating enhanced autophagic flux. (D) 
Day 9 paws were stained for phospho (p)-ULK1Ser555 (red). DAPI (blue) stained nuclei. Scale bar=25µm (E) Intracellular level of p-ULK1was analyzed using 
ImageJ program as detailed in the Materials and Methods section and presented as integrated optical density (IntDen). Values represent mean ± SEM, n=4-5 
mice per treatment group. *P<0.05 compared with saline.
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Figure 6: Metformin promotes selective degradation of NF-κB protein Iκ kinase (IKK) through autophagy. 
(A) Day 9 paw lysates from saline controls and metformin-treated animals were probed for NF-κB proteins (IKKα, IκB-β, p65, and phospho-p65). Actin served as 
protein loading control. (B) Day 9 paw sections were probed for ubiquitin (green) and p62 (red). Colocalization (arrowheads, yellow) suggests ubiquinated-p62 
aggregates. (C) Equivalent amounts of protein were immunoprecipitated with anti-ubiquitin antibody and probed with anti- IKKα antibody. High molecular weight 
protein complexes likely represent poly-ubiquinated IKKα. (D) Paw sections were also probed for IKKα and LAMP-1. Accumulation of IKKα was evident in 
the saline controls while IKKα level was significantly lower in metformin-treated animals. Colocalization of IKKα and LAMP-1 (arrows) in metformin treatment 
suggests IKKα targeted to the lysosomes.
delivery to the lysosomal pathway (perhaps through p62 association) 
for degradation. On the other hand, impaired autophagic flux [in 
saline controls] led to the accumulation of IKK (Figure 6D). Taken 
together these results suggest that metformin corrected the impaired 
autophagic flux in KRN arthritis and suppressed NF-κB-induced 
inflammation, at least partly through selective IKK degradation.
Discussion
We show herein that metformin stimulates macrophage AMPK 
activity in KRN arthritis and this stimulation inhibits the activity of 
mTORC1, enhancing autophagic flux and decreasing inflammatory 
cytokine production through STAT1 suppression and selective 
degradation of IKK through the (auto) lysosomal pathway. Metformin 
has been attracting increased attention of late, mainly as an anti-
cancer agent, alone or in combination with cytotoxic therapy [40]. 
These studies indicate that the direct effects of metformin on cancer 
cells are partially dependent on the AMPK-mTOR-signaling axis 
[40]. On the other hand the role of metformin in autophagy in RA 
has not been extensively explored. Limited studies previously suggest 
that phenformin, a biguanide with similar activity to metformin, 
improved clinical disease and decreased ESR in patients with RA [41]. 
Phenformin, however, was mostly withdrawn from the world markets 
due to safety issues [42]. More recent reports examining the effect of 
metformin in anti-collagen antibody-mediated arthritis suggests that 
the drug was effective in knocking down inflammation, although the 
authors proposed a mechanism dependent on down modulation of Th-
17 cells [17,18]. The effector mechanisms in autoantibody-mediated 
arthritis induced by passive transfer of KRN serum, however, has 
been shown to be independent of T and B cells and IL-17 [19,20]. 
Metformin has been in clinical use for over 50 years and is the first 
line oral therapy for type 2 diabetes due partly to an impressive safety 
record [43]. Although extensively used, the molecular mechanism 
of action of metformin was not established until a key study was 
performed by Zhou et al. demonstrating that metformin activates 
AMPK, a major cellular energy sensor and regulator of homeostasis 
[21]. Moreover, AMPK activity in macrophages has been shown 
to suppress inflammatory responses and promote macrophage 
polarization toward an anti-inflammatory phenotype [23]. Thus 
• Page 7 of 9 •Yan et al. J Rheum Dis Treat 2015, 1:1
AMPK activation is predominantly anti-inflammatory, likely 
occurring through mTOR inhibition and autophagy modulation [6]. 
We confirmed that metformin treatment directly activated AMPK in 
macrophages and inhibited mTORC1 activity in KRN arthritis. These 
signaling events led to enhanced autophagic flux.
Autophagy studies in RA have been focusing mainly on 
osteoclastic activity using in vitro assays. Deletion of autophagy gene 
Atg7 in TNF-α transgenic mice reduced the number of osteoclasts 
and mitigated joint damage [44]. Autophagy has also been studied 
in the context of RA synovial fibroblast survival. Kato et al. [29] 
examined RA synovial fibroblasts (RASFs) ex vivo and found that 
RASFs are hypersensitive to autophagic cell death under conditions 
of severe ER stress [29]. However, the role of autophagy in the 
modulation of inflammation in RA and experimental arthritis has not 
been extensively examined. We observed that, although autophagy 
was initiated in KRN arthritis, autophagic flux appeared severely 
impaired, as evidenced by elevated levels of lipidated LC3-II and p62 
and accumulation of ubiquinated proteins. Decline in autophagic 
flux impaired cellular clearance and stimulated NF-κB signaling, 
generating chronic inflammation [36]. On the other hand, IKK 
proteins are known substrates of autophagy [38] and degradation 
of IKK would limit the role of NF-κB in inflammation. In summary, 
impaired autophagy in KRN arthritis perpetuated the chronic cycle of 
inflammation while IKK degradation following metformin treatment 
suppressed NF-κB-mediated inflammation.
The accumulation of p62, a cargo receptor for degradation of 
ubiquinated proteins through the autophagy pathway, stimulates the 
activation of NF-κB in response to several stimuli including TNF-α 
and IL-1β [45]. In addition to its role in trafficking ubiquinated 
proteins for autophagic degradation, p62 is also involved in various 
signaling events. p62 is required for the signal transduction pathways 
activated by TNF receptor associated factor 6 (TRAF-6) and p62-
TRAF-6-mediated regulation of NF-κB [46]. How p62-TRAF-6 
complex regulates NF-κB is not clear but may involve non-degradative 
ubiquination of IKKγ as p62 silencing abrogates TRAF-6-dependent 
ubiquination of IKKγ and severely impairs NF-κB activation [47]. 
Lastly, p62-TRAF-6 complex is also a critical regulator of mTOR 
activity and autophagy [48].
Studies examining the contribution of autophagy in RA and 
autophagy modulation through pharmacotherapeutics for the 
treatment of RA are limited. A recent report suggests that mTOR 
inhibition with the rapalog everolimus suppressed synovitis and 
protected against bone/cartilage damage in experimental arthritis [49]. 
These results corroborated a previous study showing superior clinical 
benefits with a combination of everolimus and methotrexate versus 
methotrexate alone in the treatment of RA [50]. These studies and our 
results herein suggest that modulation of autophagy [through direct 
mTOR inhibition or indirectly through AMPK activation] merits 
exploration as alternative treatment strategy in RA and potentially 
other inflammatory arthritides, especially since long-term use of 
rapamycin or rapalogs carries significant risk of immunosuppression 
unless tissue [joint]-specific delivery can be achieved. 
In summary, we have shown that metformin activates AMPK and 
inhibits mTOR, correcting the impaired autophagic flux in KRN 
arthritis and suppressing NF-κB signaling. Because of the central role 
of NF-κB in immune responses, long-term general inhibition of this 
pathway may severely compromise the host’s ability to fight infection. 
The discovery that NF-κB-mediated inflammatory responses in the 
joints can be indirectly modulated by metformin through autophagy 
offers an alternative way to bypass general inhibition of NF-κB 
signaling.
Materials and Methods
K/BxN arthritis model and treatment
Six to eight week-old wild type C57BL/6 mice (The Jackson 
Laboratory, Bar Harbor, ME, USA) were injected i.p. with 175-200µl 
of KRN serum on day 0 and 1 to induce arthritis. Clinical disease 
was scored macroscopically on a scale ranging from 0–3 as previously 
described [51].
Paw thickness was measured daily by dial calipers and an average 
change in ankle thickness from the two hind paw measurements was 
determined for each mouse. Mice were randomly assigned to saline 
control or metformin (Cat # 2864, TOCRIS Bioscience) treatment 
administered i.p. daily at 150mg/kg body weight starting on day 
-1 and day 0 or 200 mg/kg starting on day 2 following KRN serum 
transfer.
Immunofluorescence
Frozen-sections of paws were fixed in 4% PFA, blocked in 8% 
BSA/PBS and incubated with the following primary antibodies: 
rabbit anti-mouse phospho-STAT1 (1:200, Cat # 9171, Cell 
Signaling Technology), IKK-alpha (1:200, Cat # 2682, Cell Signaling 
Technology), phospho-p65 (1:200, phosphorylation site S536, Cat 
# 3033, Cell Signaling Technology), phospho-mTOR (1:200; Cat# 
5536, Cell Signaling Technology), phospho-S6 (1:200; Cat #4858, Cell 
Signaling Technology), LC3 (1:200, Cat # L7543, Sigma-Aldrich), 
phospho-ULK1 (1:200, Cat # 5869, Cell Signaling Technology), rat 
anti-mouse LAMP-1 (1:100, Cat # SC19992, Santa Cruz), mouse anti-
mouse p62 (IgM, 1:500, Cat # MABC32, clone 11C9.2, Millipore), 
biotin-conjugated anti-mouse Mac-3 monoclonal antibody (1:200, 
Cat # CL8943AP, Cedarlane Laboratories), mouse anti-mouse 
ubiquitin (IgG, 1:500, Cat # 64301, clone P4D1, Biolegend) for 
1 h at room temperature followed by the appropriate secondary 
antibodies: rhodamine red-conjugated secondary antibody (1:100, 
Jackson ImmunoResearch Laboratories), FITC conjugated-
secondary antibody (1:100, Jackson ImmunoResearch Laboratories) 
or FITC conjugated-streptavidin (1:100, Cat: 7100-02, Southern 
Biotechnology Associates). All images were visualized on a Nikon 
Eclipse microscope and acquired with QCapture software.
Quantitative analysis of immunofluorescence
All images were visualized on a Nikon Eclipse fluorescence 
microscope and acquired with QCapture software using the same 
exposure time. The single-color images were loaded into Image J 
software (http://rsb.info.nih.gov/ij/) for analysis. Threshold brightness 
of the image was adjusted to facilitate selection of regions of interest 
(ROIs) and free hand tool used to eliminate nonspecific staining. 
All images were set with the same hue, saturation, and brightness 
for further image analysis/measurement. The data represent average 
obtained from 4-5 mice per treatment group, 10-15 fields per paw 
section and 5-6 sections per paw and presented as integrated optical 
density (IntDen).
Histological analysis
Paws were harvested on day 9 after serum transfer, fixed in 10% 
buffered formalin for 48 h before decalcification in EDTA solution 
and processing for paraffin embedding. The sections (5µm) were 
stained with Hematoxylin and Eosin (H&E) or toluidine blue. 
Inflammatory cells infiltrating the synovial lining and the joint cavity 
were enumerated in 8-10 random fields per section using H&E images 
acquired at 400x magnification. Proteoglycan depletion was scored 
on toluidine blue-stained sections on a scale from 0–3, ranging from 
fully stained cartilage (score=0) to fully destained cartilage (score = 
3) as previously described [51]. The number of bone erosions was 
enumerated per mm of bone surface using ImageJ program (http://
rsb.info.nih.gov/ij/). Scoring was performed by an observer blinded 
to the treatment.
Culture of peritoneal macrophages
Peritonitis was induced by i.p. injection of sterile thioglycollate 
(4 % w/v in 1mL of sterile saline). The peritoneal macrophages were 
isolated from the peritoneal lavage on day 5 as previously described 
[27]. The recovered macrophages were washed with sterile PBS, 
counted and seeded in triplicates at 2×105 cells per well on 96-well 
plate. The cells were allowed to adhere for 1 h at 37°C and non-
adherent cells were removed with gentle washing. Serial doses of 
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metformin (0.03, 0.06, 0.12, 0.25, 0.5, 2.5 and 10mM) were added 
and the cells were cultured at 37°C in 5% CO2 atmosphere. The 
supernatant was collected at 48 h for cytokine analysis and the cell 
lysates were prepared for Western blotting.
Cytokine analysis
Paws were homogenized in 1 ml of PBS with proteinase inhibitor 
cocktail and cleared by centrifugation. Cytokine concentrations 
were measured in equivalent volumes of paw lysates or culture 
supernatant using an ELISA kit for IL-1β (R&D Systems Inc., 
Minneapolis, Minnesota, USA) and cytometric bead Array (CBA, 
Mouse Inflammatory Cytokines kit, BD Bioscience) for TNF-α, IL-6, 
IL-10, IL-12p70, MCP-1 and INF-γ according to the manufacturer’s 
recommendations.
Western blot analysis
Snap-frozen paws or macrophages were processed in 1% NP-40 
lysis buffer containing proteinase inhibitor cocktail (Sigma-Aldrich) 
and 50mM sodium fluoride (Sigma-Aldrich) and protein lysates cleared 
by centrifugation. Equivalent amounts of protein were resolved on a 
10% SDS-PAGE gel and transferred to PVDF membrane (Millipore). 
The membrane was probed using the following primary antibodies: 
rabbit anti-mouse LC3 (1:2,000, Cat # L7543, Sigma-Aldrich), 
phospho-AMPKα (1:1,000, Cat # 2535, Cell Signaling Technology), 
phospho-mTOR (1:1,000, Cat # 5536, Cell Signaling Technology), 
IKK-α (1:1,000, Cat # 2682, Cell Signaling Technology), IκB-β (1:200, 
Cat # SC-945, Santa Cruz), total p65 (1:2,000, Cat # 8242, Cell Signaling 
Technology), phospho-p65 (1:2,000, Cat # 3033, Cell Signaling 
Technology) and mouse anti-mouse p62 (1:2,000, Cat # MABC32, 
clone 11C9.2, Millipore) followed by the appropriate HRP-conjugated 
secondary antibodies. Goat anti-mouse actin (1:3,000, Cat # SC-1615, 
Santa Cruz) served as control for quantity and quality of protein.
Immunoprecipitation of ubiquinated proteins
Paw protein lysates were prepared as described above. Equivalent 
amounts of precleared protein lysate (200µg and 20µl of protein G 
Sepharose beads (Sigma-Aldrich; Cat# P3296; in 20% ethanol) were 
incubated with monoclonal anti-ubiquitin antibody (IgG, 1:200, 
Cat # 64301, clone P4D1, Biolegend) overnight at 4°C under rotary 
agitation. The beads were washed three times in NP-40 buffer, boiled 
at 95-100°C for 5 min in SDS buffer, and fractionated on a SDS-
PAGE gel. The proteins were transferred to PVDF membrane and 
probed with anti-IKK-α antibody (1:1,000, Cat # 2682, Cell Signaling 
Technology).
Statistical analysis
Comparisons between two groups and multiple groups (≥3) were 
performed by t-test and 2-way ANOVA, respectively, followed by 
Bonferroni post hoc test to compare all groups of data. Numerical 
data were expressed as mean ± SEM. P values <0.05 were considered 
significant.
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